Example: confidence
Posicionamento sobre Melatonina SBEM
10. Lekha Sahaa, Sharonjeet Kaura, Pradip Kumar Saha. Pharmacotherapy of polycystic ovary syndrome – an update. Fundamental & Clinical Pharmacology 26, 54–62, 2012 11. Daniel P. Cardinali, Pilar Cano, Vanesa Jiménez-Ortega, Ana I. Esquifino. Melatonin and the Metabolic Syndrome: Physiopathologic and Therapeutical Implications.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Posicionamento Oficial da Sociedade Brasileira de ...
www.endocrino.org.brPosicionamento Oficial da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) sobre utilização dos testes de Função Tireoidiana na Prática Clínica. SBEM Nacional Rua Humaitá, 85 - 5º andar 22261-000 - Humaitá - Rio de Janeiro/RJ Fone: (21) 2579.0312
Related documents
Executive summary of the 2020 KDIGO Diabetes Management …
kdigo.orgpharmacotherapy in selected patients (Figure 2).6 Patients with T1D or T2D, hypertension, and albuminuria (persistent albumin-creatinine ratio $30 mg/g [3 mg/mmol]) should be treated with a renin–angiotensin system inhibitor (RASi). Multiple clinical trials in these populations demon-strate that RASi reduces risk of CKD progression in a manner
Treatment of Hypertension: JNC 8 and More
pharma-smart.comhypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2013 Dec 17. doi: 10.1111/jch.12237. [Epub ahead of print]. 3. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older.
Anxiety Disorders: Diagnosis & Treatment
www.ihs.govOther Pharmacotherapy Options Buspirone (5-60 mg/d divided doses) Serotonin agonist/antagonist Approved for GAD No prominent side effects Pregabalin (>150mg/d divided doses) Off-label use for GAD Quetiapine (25-100mg TID prn) Off-label use for GAD, panic disorder Weight gain, metabolic effects